Brain and behavior · 2025
Specific Marker Gene Analysis for Primary Central Nervous System Lymphoma Based on Methylation Difference and Development of Detection Primers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yan Feng, Wang Yaming, Fan Xiaotong, Wei Penghu, Shan Yongzhi
Аннотация
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a central nervous system disease with high mortality, wide variation in symptoms, and difficult diagnosis. The development of molecular markers for PCNSL is still in its initial stages.
METHODS: The databases were analyzed by 450 K and RRBS, and the differential gene structure was displayed through Venn diagram, heatmap, and enrichment. ROC and survival curve analyses were performed on the marker genes. The specificity of PCNSL in blood samples of patients was verified by qPCR, and the sensitivity of the detection primers was verified by in vitro methylation and demethylation drug treatment cell experiments.
RESULTS: Twenty-six sites were identified using 450 K microarray analysis. The RRBS analysis team found 14,867 sites. The methylation site located in the promoter region of REHB was verified, and the results showed that the primers for this site were able to distinguish patients with PCNSL and were sensitive to the detection of methylation levels.
CONCLUSIONS: A pair of methylation primers targeting the RHEB promoter region were obtained, which demonstrated the potential to distinguish patients with PCNSL from those with other CNS diseases. These findings should be considered preliminary and serve as proof-of-concept for further validation in larger cohorts.
METHODS: The databases were analyzed by 450 K and RRBS, and the differential gene structure was displayed through Venn diagram, heatmap, and enrichment. ROC and survival curve analyses were performed on the marker genes. The specificity of PCNSL in blood samples of patients was verified by qPCR, and the sensitivity of the detection primers was verified by in vitro methylation and demethylation drug treatment cell experiments.
RESULTS: Twenty-six sites were identified using 450 K microarray analysis. The RRBS analysis team found 14,867 sites. The methylation site located in the promoter region of REHB was verified, and the results showed that the primers for this site were able to distinguish patients with PCNSL and were sensitive to the detection of methylation levels.
CONCLUSIONS: A pair of methylation primers targeting the RHEB promoter region were obtained, which demonstrated the potential to distinguish patients with PCNSL from those with other CNS diseases. These findings should be considered preliminary and serve as proof-of-concept for further validation in larger cohorts.